Clinical Trials

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT05950165 2026-03-03

A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma

Phase 1/2 Recruiting

37 enrolled

Lymphoma, Follicular, Lymphoma, Non-Hodgkin

NCT07418190 2026-02-18

Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma

Phase 2 Recruiting

33 enrolled

Lymphoma, Follicular

NCT04669171 2026-01-30

SIDNEY

Phase 1/2 Recruiting

80 enrolled

Phase 3 Not yet recruiting

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT07355283 2026-01-27

IMM0306 in Combination With Lenalidomide vs Placebo in Combination With Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma

198 enrolled

Lymphoma, Follicular

NCT04792502 2025-12-30

Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma

Phase 2 Recruiting

52 enrolled

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT04680052 2025-12-22

InMIND

654 enrolled 40 charts 1 FDA

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT02390869 2025-12-02

FIL_RENOIR12

128 enrolled

Lymphoma, Follicular, Recurrence

NCT02568553 2025-11-26

Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma

Phase 1 Completed

35 enrolled

Phase 1/2 Active not recruiting

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT02180711 2025-10-15

Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma

113 enrolled 19 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Marginal Zone

NCT05371093 2025-10-15

ZUMA-22

231 enrolled

Phase 1/2 Active not recruiting

Lymphoma, Follicular

NCT03015896 2025-09-29

Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma

36 enrolled

Burkitt Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT01650701 2025-09-25

RELEVANCE

Phase 3 Completed

1,030 enrolled

Phase 1 Active not recruiting

Lymphoma, Follicular

NCT04447716 2025-09-15

An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment

4 enrolled

Phase 1 Active not recruiting

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT02992522 2025-09-09

Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

22 enrolled

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT06792825 2025-08-12

HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL

Phase 2 Recruiting

65 enrolled

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT05409066 2025-07-28

EPCORE FL-1

549 enrolled 2 FDA

503 enrolled 18 charts 1 FDA

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms

NCT01996865 2025-07-10

MAGNIFY

Phase 3 Completed

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT01995669 2025-06-24

Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma

Phase 1/2 Completed

66 enrolled 13 charts

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT01476787 2025-05-14

RELEVANCE

Phase 3 Completed

1,030 enrolled 12 charts

Lymphoma, Follicular

NCT00848328 2025-04-24

Lenalidomide and Rituximab in Treating Patients With Non-Hodgkin Lymphoma

Phase 2 Terminated

30 enrolled

Lymphoma, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04578600 2025-04-24

CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma

Phase 1 Completed

8 enrolled

Leukemia, Hairy Cell, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04036448 2025-03-11

RevlimidPMS

Completed

28 enrolled

LymphoidMyeloid

Lymphoma, Follicular, Myelodysplastic Syndromes, Recurrence, Lymphoma, Mantle-Cell

NCT00670358 2025-01-10

Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma

Phase 1/2 Completed

138 enrolled 16 charts

Lymphoma, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT04110301 2024-11-20

MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)

Phase 1/2 Recruiting

53 enrolled

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT06284122 2024-10-15

MorningLyte

Phase 3 Recruiting

790 enrolled

Phase 2 Not yet recruiting

Lymphoma, Follicular

NCT06549335 2024-10-15

Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Patients with Follicular Lymphoma (FL)

66 enrolled

Lymphoma, Lymphoma, Follicular

NCT02532257 2024-09-24

Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma

Phase 2 Completed

48 enrolled 15 charts

Phase 1/2 Active not recruiting

Lymphoma, Follicular

NCT03980171 2024-07-29

LEVERAGE

50 enrolled